Salmon Hormone May Contain Too Much Cancer Risk

A salmon hormone used to treat post-menopausal osteoporosis may not reduce bone fractures enough to outweigh the drug’s cancer risks, U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.